Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Caribou Biosciences (CRBU) over the last 5 years, with Q3 2025 value amounting to $93.3 million.

  • Caribou Biosciences' Shares Outstanding (Diluted Average) rose 313.66% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 313.66%. This contributed to the annual value of $90.3 million for FY2024, which is 2236.94% up from last year.
  • As of Q3 2025, Caribou Biosciences' Shares Outstanding (Diluted Average) stood at $93.3 million, which was up 313.66% from $93.0 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Shares Outstanding (Diluted Average) ranged from a high of $93.3 million in Q3 2025 and a low of $10.3 million during Q2 2021
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $67.6 million (2023), whereas its average is $69.5 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 49207.81% in 2022, then skyrocketed by 105.76% in 2023.
  • Over the past 5 years, Caribou Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $31.7 million in 2021, then soared by 92.02% to $60.8 million in 2022, then increased by 21.39% to $73.8 million in 2023, then grew by 22.37% to $90.3 million in 2024, then grew by 3.29% to $93.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $93.3 million in Q3 2025, compared to $93.0 million in Q2 2025 and $92.7 million in Q1 2025.